Analysis of Agios Pharmaceuticals Executive Share Sale Transactions and Interpretation of Insider Trading Signals

I. Core Facts of Executive Share Sale Transactions

Based on SEC disclosure documents and online search data, the transaction details of Sarah Gheuens (Chief Medical Officer/CMO) are as follows:

Transaction Element	Specific Information
Transaction Time	October 27, 2025 (Monday) [2]
Transaction Type	Sale (reduction), non-10b5-1 plan transaction
Number of Shares Traded	3,302 shares [2]
Average Transaction Price	Approximately $43.92 [2]
Transaction Amount	Approximately $145,023.84 [2]
Remaining Shares Held	61,727 shares [2]
Remaining Market Value	Approximately $2,711,049.84 [2]
Reduction Percentage	Approximately 5.08% of personal holdings [2]

Other Relevant Insider Trading Information:

Past 90 Days
: Insiders sold a total of 7,553 shares, worth approximately $305,001 [2]
Insider Ownership Percentage
: Approximately 4.30% of the company’s outstanding shares [2]
Past 6-Month Pattern
: 18 insider transactions, all sales (18) and no purchases (0) [4]

II. Company Fundamentals and Market Environment

2.1 Company and Stock Price Performance

According to brokerage API data, the current status of Agios Pharmaceuticals is as follows:

Indicator	Specific Value
Current Stock Price	$27.18 (closing price on January 2, 2026) [0]
52-Week Range	$22.24 - $46.00 [0]
Market Capitalization	Approximately $1.58 billion [0]
Recent Performance	From October 1 to December 31, 2025, the stock price fell from $40.09 to $27.22, with a range decline of approximately 32.10% [8]

2.2 Financial Health Status

Financial analysis shows [7]:

Free Cash Flow
: -$89,706,000 (latest quarter) [7]
Financial Approach
: Conservative accounting treatment, high depreciation/amortization policy [7]

Related Stocks